NF-κB inhibitor BAY 11-7082 and proteasome inhibitors bortezomib and MG132 can inhibit the NF-κB gene and so its pathway on the HSCs, which can in turn reduce liver fibrosis (Anan et al., 2006). Here, NFKB1 is linked to Hepatic fibrosis.